A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
Primary Objectives:
- To evaluate the efficacy of GS-5245 in reducing the duration of COVID-19 symptoms
- To evaluate the safety and tolerability of GS-5245 administered in nonhospitalized participants with COVID-19
Primary Investigator: John Cafardi